drugset / Trial / NCT03897491

PD L 506 for Stereotactic Interstitial Photodynamic Therapy of Newly Diagnosed Supratentorial IDH Wild-type Glioblastoma

NCT03897491

Phase 2 Terminated 17 enrolled photonamic GmbH & Co. KG
NaSingle-groupOpen-labelTreatment

Summary

The trial is an open, multicenter, explorative, pilot phase II study in a small number of patients to assess safety and efficacy of stereotactic interstitial photodynamic therapy (iPDT) with PD L 506 in newly diagnosed supratentorial IDH wild-type glioblastoma.

Timeline

Start
2021-09-03
Primary completion
2026-04-08
Completion
2026-04-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Aminolevulinic Acid Diagnostic / imaging agent 20 mg/kg Oral

Indications